Necati Kaval

The development of corannulene-based blue emitters

Novel blue emitters were synthesized based on the fullerene fragment corannulene. 1,2- bis(corannulenylethynyl)benzene and 1,4-bis(corannulenylethynyl)benzene were designed, synthesized, and shown to exhibit significant red shifts in their absorption spectra as compared to that of the parent corannulene. Photoluminescence studies show both 1,2- bis(corannulenylethynyl)benzene and 1,4- bis(corannulenylethynyl)benzene gives enhanced blue luminescence compared to the parent corannulene structure. 1,4-bis(corannulenylethynyl)benzene was observed to give intense blue luminescence when excited at 400 nm. DFT and TD-DFT calculations were performed and shown to be consistent with the observed experimental results.

Luminescence-Based Spectroelectrochemical Sensor for [Tc(dmpe)3]2+/+ (dmpe = 1,2-bis(dimethylphosphino)ethane) within a Charge-Selective Polymer Film

A spectroelectrochemical sensor consisting of an indium tin oxide (ITO) optically transparent electrode (OTE) coated with a thin film of partially sulfonated polystyrene-blockpoly(ethylene-ran-butylene)-block-polystyrene (SSEBS) was developed for [Tc(dmpe)(3)](+) (dmpe = 1,2-bis(dimethylphosphino)ethane). [Tc(dmpe)(3)](+) was preconcentrated by ion-exchange into the SSEBS film after a 20 min exposure to aqueous [Tc(dmpe)(3)](+) solution, resulting in a 14-fold increase in cathodic peak current compared to a bare OTE. Colorless [Tc(dmpe)(3)](+) was reversibly oxidized to colored [Tc(dmpe)(3)](2+) by cyclic voltammetry. Detection of [Tc(dmpe)(3)](2+) was accomplished through emission spectroscopy by electrochemically oxidizing the complex from nonemissive [Tc(dmpe)(3)](+) to emissive [Tc(dmpe)(3)](2+). The working principle of the sensor consisted of electrochemically cycling between nonemissive [Tc(dmpe)(3)](+) and emissive [Tc(dmpe)(3)](2+) and monitoring the modulated emission (λ(exc) = 532 nm; λ(em) = 660 nm). The sensor gave a linear response over the concentration range of 0.16-340.0 μM of [Tc(dmpe)(3)](2+/+) in aqueous phase with a detection limit of 24 nM.

A low-cost, plug-and-play inertial microfluidic helical capillary device for high-throughput flow cytometry

Glass capillary tubes have been widely used in microfluidics for generating microdroplets and microfibers. Here, we report on the application of glass capillary to inertial focusing of microparticles and cells for high-throughput flow cytometry. Our device uses a commercially available capillary tube with a square cross-section. Wrapping the tube into a helical shape induces the Dean vortices that aid focusing of cells or microbeads into a single position. We investigated the inertial focusing of microbeads in the device at various Re and concentrations and demonstrated 3D focusing with ∼100% efficiency for a wide range of microparticle diameters. We integrated the device with a laser counting system and demonstrated continuous counting of 10 μm microbeads with a high throughput of 13 000 beads/s as well as counting of fluorescently labeled white blood cells in the diluted whole blood. The helical capillary device offers a number of key advantages, including rapid and ultra-low-cost plug-and-play fabrication, optical transparency, and full compatibility with bright field or fluorescent imaging, easy re-configurability of the device radius for tuning focusing behavior, and ability to rotate for easy side-wall observation. With precise and consistent 3D focusing of microbeads and cells with a wide range of sizes at high throughput and without the use of sheath flows, we envision that this simple capillary-based inertial microfluidic device will create new opportunities for this technique to be widely adopted in the laboratory research.

Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs

Graphical abstract Figure. No caption available. ABSTRACT Repetitive intravitreal injections of Methotrexate (MTX), a hydrophilic chemotherapeutic drug, are currently used to treat selected vitreoretinal (VR) diseases, such as intraocular lymphoma. To avoid complications associated with the rapid release of MTX from the injections, a Polylactic acid (PLA) and Chitosan (CS)‐based MTX micro‐implant prototype was fabricated in an earlier study, which showed a sustained therapeutic release rate of 0.2–2.0 &mgr;g/day of MTX for a period ˜1 month in vitro and in vivo. In the current study, different combinations of Poly(lactic‐co‐glycolic) acid (PLGA)/PLA coatings were used for lipophilic surface modification of the CS‐MTX micro‐implant, such as PLGA 5050, PLGA 6535 and PLGA 7525 (PLA: PGA – 50:50, 65:35, 75:25, respectively; M.W: 54,400 – 103,000) and different PLA, such as PLA 100 and PLA 250 (MW: 102,000 and 257,000, respectively). This improved the duration of total MTX release from the coated CS‐MTX micro‐implants to ˜3–5 months. With an increase in PLA content in PLGA and molecular weight of PLA, a) the initial burst of MTX and the mean release rate of MTX can be reduced; and b) the swelling and biodegradation of the micro‐implants can be delayed. The controlled drug release mechanism is caused by a combination of diffusion process and hydrolysis of the polymer coating, which can be modulated by a) PLA content in PLGA and b) molecular weight of PLA, as inferred from Korsmeyer Peppas model, Zero order, First order and Higuchi model fits. This improved micro‐implant formulation has the potential to serve as a platform for controlled release of hydrophilic drugs to treat selected VR diseases.